Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.07
+0.54003.99%
Post-market: 14.05-0.0200-0.14%19:47 EDT
Volume:1.35M
Turnover:18.88M
Market Cap:570.71M
PE:-2.81
High:14.20
Open:13.42
Low:13.42
Close:13.53
Loading ...

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Illumina (ILMN)

TIPRANKS
·
11 Apr

BUZZ-U.S. STOCKS ON THE MOVE-AppLovin, Ligand Pharma, Dexcom

Reuters
·
11 Apr

Keros Therapeutics Shares up 16% After Co Adopts 'Poison Pill' Plan

THOMSON REUTERS
·
10 Apr

Sector Update: Health Care

MT Newswires Live
·
10 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, General Motors, AES

Reuters
·
10 Apr

Keros Therapeutics Board Initiates Review of Strategic Alternatives

MT Newswires Live
·
10 Apr

Keros Therapeutics Shares Rise Premarket as Company Mulls Sale

Dow Jones
·
10 Apr

Keros Therapeutics Shares up 17.7% Premarket After Co Adopts 'Poison Pill' Plan

THOMSON REUTERS
·
10 Apr

Keros Therapeutics adopts 'poison pill' plan

Reuters
·
10 Apr

Keros Therapeutics Inc - Adopted Limited-Duration Stockholder Rights Plan

THOMSON REUTERS
·
10 Apr

Truist Cuts Price Target on Keros Therapeutics to $25 From $43, Keeps Buy Rating

MT Newswires Live
·
09 Apr

Keros Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Scotiabank Remains a Buy on Keros Therapeutics (KROS)

TIPRANKS
·
01 Apr

Keros Therapeutics reports results from Phase 1 clinical trial of KER-065

TIPRANKS
·
31 Mar

BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers

Reuters
·
31 Mar

Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial of Ker-065 in Healthy Volunteers

THOMSON REUTERS
·
31 Mar

Keros Therapeutics Inc -Plans on Advancing Ker-065 Into a Phase 2 Clinical Trial in Dmd, Subject to Positive Regulatory Interaction

THOMSON REUTERS
·
31 Mar

Keros Therapeutics Inc: Ker-065 Was Generally Well-Tolerated, With No Major Safety Signals Observed to Date

THOMSON REUTERS
·
31 Mar

Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet

Zacks
·
21 Mar

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade

Zacks
·
05 Mar